SEC Form 4 · accession 0001562180-18-002039
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO & Treasurer
Period of report
Apr 26, 2018
Accepted (ET)
Apr 27, 2018 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 26, 2018 | S | 100 | $141.21 | D | 38,245 | D | |
| Common StockF2 | Apr 26, 2018 | S | 3,207 | $143.09 | D | 35,038 | D | |
| Common StockF3 | Apr 26, 2018 | S | 3,300 | $143.90 | D | 31,738 | D | |
| Common StockF4 | Apr 26, 2018 | S | 6,075 | $144.98 | D | 25,663 | D | |
| Common Stock | Apr 26, 2018 | S | 100 | $145.80 | D | 25,563 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $142.40 USD to $143.39 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $143.43 USD to $144.35 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $144.52 USD to $145.42 USD. The price reported above reflects the weighted average sale price.